Advanced Progress of Targeted Therapeutic Drugs in Treating Non-Small Cell Lung Cancer
10.3870/j.issn.1004-0781.2017.08.011
- VernacularTitle:非小细胞肺癌靶向治疗研究进展
- Author:
Qiuli MIAO
;
Sixi ZHANG
;
Hongyu WANG
;
Hong WANG
- Keywords:
Cancer,lung,non-small cell;
Targeted therapy;
Precision Medicine
- From:
Herald of Medicine
2017;36(8):887-892
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapeutic drug,having such advantages as targeting,safety,convenience,etc,is increasingly favored by non-small cell lung cancer (NSCLC) patients.At present,there are many kinds of molecular targeted drugs used in clinic,and remarkable efficacy was achieved,and the pain caused by conventional chemotherapy was avoided.At the same time,with the deepening of the understanding of the mechanism of tumor immune,new targeted drugs will also continue to be developed.The emergence of the third generation EGFR-TKI brings new hope for first generation EGFR-TKI resistant patients.Combined use of different immune therapeutic agents,combined application of immunotherapy drugs and cytotoxic chemotherapy drugs and radiotherapy,and the exploration of its predictive biomarkers will become a hot spot in the research of lung cancer.This will undoubtedly bring a new dawn for the treatment of NSCLC.Based on the domestic and foreign research literatures and related materials,this article reviews the latest research progress of various molecular targeted drugs for treatment of NSCLC.
